First-in-Human Trial of DS1025a in Participants with Advanced Solid Tumors
This early-stage study is testing a new experimental medicine called DS1025a in people for the very first time. It is designed for adults living with advanced solid tumours—cancers that have spread to other areas of the body or cannot be completely removed with surgery. Because this is a Phase 1 trial, the main goal is not yet to see how well the medicine treats the cancer, but to check whether it is safe. Doctors will look closely at what side effects the medicine causes, how the body handles it, and what dose is safe to give. Participants will be monitored very carefully with frequent hospital appointments, blood tests, and scans. Taking part is entirely voluntary, and the study helps scientists decide if DS1025a could become a helpful cancer treatment in the future.
At a glance
What is this study about?
Solid tumours are growths or lumps of cancer cells that develop in organs or tissues, such as the lungs, bowel, or skin. When a cancer is called 'advanced', 'metastatic', or 'unresectable', it means the tumour has grown into nearby tissues, spread to distant parts of the body, or cannot be safely removed with surgery. When standard treatments stop working or are no longer an option, doctors look for new approaches through research.
This trial is testing a brand-new experimental drug called DS1025a. Because this is a 'first-in-human' study, it is the first time real patients are receiving the medicine after laboratory testing. The main purpose is to find a safe dose and discover how the drug affects the body. Small groups of patients usually receive lower doses first, and doctors monitor them closely before carefully raising the dose for new groups.
Trials like this are an important first step in creating new cancer therapies. While doctors cannot guarantee that this experimental drug will shrink your tumour, taking part provides vital medical knowledge that helps researchers understand if DS1025a could improve cancer care for patients in the future.
Key takeaways
- This trial tests a new cancer medicine, DS1025a, in humans for the first time.
- It is for adults with advanced solid tumours that cannot be surgically removed or have spread.
- The primary aim is to test safety, discover side effects, and find the right dose.
- Participants will have frequent hospital visits, blood tests, and scans for close monitoring.
- Taking part is voluntary, and you can leave the study at any time.
Who may be eligible?
This trial is open to adults aged 18 and older who have an advanced solid tumour. To join, a person's cancer must be either metastatic (spread to other organs) or unresectable (cannot be removed by an operation).
In studies like this, participants have typically already received standard cancer treatments that are no longer working, or there may be no approved treatments left that are suitable for their condition.
Because your safety is the top priority, your major organs—such as your heart, liver, and kidneys—must be working reasonably well. The research team will run tests to confirm whether your general health is stable enough to manage an experimental treatment safely.
Could this study suit you?
Answer these quick questions to see if you may be eligible. This is a guide only — the research team makes the final call.
- I am 18 years of age or older.
- I have been diagnosed with a solid tumour (not a blood cancer).
- My cancer is advanced, has spread, or cannot be removed by an operation.
- I have already tried standard treatments, or none are suitable for me.
- I am well enough to attend regular hospital appointments and tests.
What does participation involve?
If you choose to take part, you will first attend a screening visit where doctors check your health with blood tests, heart checks, and scans. If you are eligible, you will receive the study medicine, DS1025a, at a specialist hospital clinic. Because this is an early safety trial, you will need to make frequent hospital visits, especially in the first few weeks. During these visits, the medical team will check your vital signs, collect blood samples to see how the medicine moves through your body, and ask how you are feeling. You will have regular imaging scans (like CT or MRI scans) to keep track of your tumour. Treatment may continue as long as your cancer does not get worse and the side effects remain manageable. After you finish the medicine, doctors will continue to check on your health during a follow-up period.
Potential risks and benefits
Locations (1)
- —UnverifiedFrance
Common questions
What does 'first-in-human' mean?
It means this study is the very first time this experimental drug is being given to people, having previously only been tested in laboratory settings.
Will DS1025a cure my cancer?
It is unlikely to cure your cancer. The main goal of an early-phase trial is to find a safe dose and see how the body reacts, rather than to provide a cure.
Do I have to pay to take part in this trial?
No, you do not pay for trial medicines or extra tests. In many cases, trials can also help cover your travel and parking costs.
Can I leave the study if I change my mind?
Yes. You have the right to leave the trial at any point, for any reason, and your regular medical team will continue to support you.
What happens if I experience unpleasant side effects?
You must tell the research team straight away. They can offer treatments to ease symptoms, lower your dose, or stop the study medicine if needed.
How to find out more
Always speak to your GP or specialist before deciding to take part in a study.
Discussion
Community discussion
Powered by our forum at community.patient.info. Please be respectful — this is not medical advice.